One Japan Stem Cell Institute Soars, One Struggles

Fox, Cynthia
June 2014
Bioscience Technology;Jun2014, p1
Trade Publication
The article reports on Center for iPS Cell Research and Application (CiRA) Nobel Prize winner and scientist Shinya Yamanaka in Japan. It mentions his statement over their proposed clinical trials on induced pluripotent stem cells (IPSCs). It also notes the problem of his sister institute, the Riken Institute, with acid bath stem cells which are considered to be inexistent.


Related Articles

  • Japan stem-cell trial stirs envy. Reardon, Sara; Cyranoski, David // Nature;9/18/2014, Vol. 513 Issue 7518, p287 

    The article discusses the clinical trials of induced pluripotent stem (iPS) cells. It states that the iPS cells are created by using a patient's own tissue and by inserting them in an adult's DNA cells to reprogram the cells to an embryonic-like state. The therapy was pioneered by Shinya...

  • Stem-cell pioneer banks on future therapies. Cyranoski, David // Nature;8/9/2012, Vol. 488 Issue 7410, p139 

    The article focuses on the plans of Shinya Yamanaka of Kyoto University to build stem cell bank to be used for therapeutic purposes. It says that the scheme called the Induced Pluripotent Stem (iPS) Cell Stock, gained support from the country's health ministry committee. It mentions various...

  • Induced Pluripotent Stem Cells. Wilson, Kitchener D.; Wu, Joseph C. // JAMA: Journal of the American Medical Association;4/28/2015, Vol. 313 Issue 16, p1613 

    The article discusses the 2006 discovery of a method for creating induced pluripotent stem cells (iPSCs) by Takahashi and Shinya Yamanaka and colleagues, which won Yamanaka a Nobel Prize in 2012. Topics include the use of pluripotency to regenerate human organs and tissues, the time consumption...

  • REWIND STEM CELLS, THEN FAST FORWARD. Coghlan, Andy // New Scientist;12/22/2012, Vol. 216 Issue 2896/2897, p21 

    The article discusses the development of a process to transform adult cells into a stem cell state, focusing on induced pluripotent stem cells reverted by the researcher Shinya Yamanaka and a clinical trial planned by the biotechnology company Advanced Cell Technology Inc.

  • As STAP Papers are Retracted, A Riken Researcher Mulls Stalling World-First Trial. Fox, Cynthia // Bioscience Technology;7/2/2014, p1 

    The article reports that Riken Center for Developmental Biology (CDB) researcher Masayo Takahashi is considering suspending a part of a world-first clinical trial of induced pluripotent stem cell (iPSC). Topics discussed include the "Nature" journal's retraction of Riken CDB researchers Haruko...

  • Nobel for stem cell trick...  // New Scientist;10/13/2012, Vol. 216 Issue 2886, p6 

    The article reports that cell scientists John Gurdon and Shinya Yamanaka were awarded the 2012 Nobel prize in physiology or medicine for their research into the reprogramming of mature cells into induced pluripotent stem cells (iPSCs) which can differentiate like embryonic stem cells.

  • Perspectives on human clinical trials of therapies using iPS cells in Japan: Reaching the forefront of stem-cell therapies. Peipei Song; Yoshinori Inagaki; Yasuhiko Sugawara; Norihiro Kokudo // BioScience Trends;Jun2013, Vol. 7 Issue 3, p157 

    A research project involving sheets of retinal pigment epithelium constructed from iPS cells derived from patients with age-related maculopathy is one step closer to being approved for clinical trials by the Japanese Government. Now is the time to make therapies using iPS cells clinically available.

  • Historic Japan Stem Cell Trial Approved. Fox, Cynthia // Bioscience Technology; 

    The article discusses the clinical trial of revolutionary stem cells approved by Japan Health Minister to be led by retina regeneration expert Masayo Takahashi. The cells called induced pluripotent stem (iPS) Cells will be morphed into retinal cells and given to 6 patients with age-related...

  • Induced pluripotent stem cells for spinal cord injury therapy: current status and perspective. Wang, H.; Fang, H.; Dai, J.; Liu, G.; Xu, Z. // Neurological Sciences;Jan2013, Vol. 34 Issue 1, p11 

    Spinal cord injury (SCI) is induced by a variety of damages such as trauma, ischemia, and iatrogenic injury, resulting in sense and motion dysfunction. Despite the improvements in medical and surgical care, current treatment methods for SCI demonstrate poor and delayed efficiency, leading to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics